Methylene Blue Treatment of COVID-19

Status Active, not recruiting

Clinical Trial Summary

Despite enormous progress in understanding COVID-19, there is little evidence that a solution, therapeutic or preventive, is close to being achieved. Repurposing of well known, widely available drugs represent an attractive approach to speed up availability of active treatments. Such substances as i.e. hydroxychloroquine and others, are already under investigation and in widespread off label use. For many reasons Methylene blue (MB), the oldest synthetic substance in medicine (1876 synthesized by BASF) is such a promising candidate for an active treatment against SARS-CoV-2 infected people and for COVID-19 patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04635605
Study type	Interventional
Source	Fondazione Epatocentro Ticino
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	November 5, 2020
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04446065` - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers	Phase 2/Phase 3
Completed	`NCT04419025` - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease	Phase 2
Not yet recruiting	`NCT04400019` - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)	Phase 2/Phase 3
Completed	`NCT04463004` - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation	Phase 2
Completed	`NCT04446429` - Anti-Androgen Treatment for COVID-19	N/A
Completed	`NCT04402957` - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)	Phase 2
Recruiting	`NCT04441372` - Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
Recruiting	`NCT04581148` - SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Terminated	`NCT04371978` - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Phase 3
Completed	`NCT04530604` - Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)	Phase 1
Recruiting	`NCT04395599` - Risk of Air Contamination During Visceral Surgery in COVID19 Patients	N/A
Recruiting	`NCT04472585` - Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients	Phase 1/Phase 2
Active, not recruiting	`NCT04411433` - Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19	Phase 3
Completed	`NCT04359706` - Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Recruiting	`NCT04395794` - SARS-CoV-2 Disguise Study
Completed	`NCT04386551` - Detection of COVID-19 in Saliva Collection
Recruiting	`NCT04403269` - NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE	Phase 2
Withdrawn	`NCT04379492` - A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19	Phase 2
Completed	`NCT04407182` - Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19	Phase 2
Completed	`NCT04366934` - Study of the Pathogenesis of Olfactory Disorders in COVID-19